Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.
Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.